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Introduction: In this study, we examined changes in depot medroxyprogesterone acetate (DMPA) 
prescriptions over a time-period when new professions started prescribing, and when the method 
gained some negative media attention. Material and methods: The Norwegian Prescription 
Database provided data on hormonal contraception from 2006 through 2012. We estimated 
annual number of DMPA users by calculating doses sold per day/1000 women and calculated, for 
each contraceptive method on annual basis, a proportion of defined daily doses of all hormonal 
contraceptives in 5-year age groups at reproductive age. All analyses were done in SPSS, version 
22, with chi-square test, t-test, and survival analysis with p < 0.05 as significance level. Results: 
There were minor differences in overall DMPA use during the study years. The take-out rate was 
equivalent to 11–12 per 1000 women aged 15–49 years. DMPA sales amounted to nearly 4% of 
all daily doses of hormonal contraceptives sold. General practitioners and physicians without a 
specialty were the major prescribers.  The number of starters decreased by nearly 40% during the 
study years and was consistent across age groups. The average use duration among starters was 
17.7 (95% CI: 17.5–17.9) months (range 0–90). There were minor changes in the relative 
proportion of long-term users beyond 24 months during the study years. Conclusions: DMPA 
plays a minor role in the overall use of hormonal contraception in Norway, even among 
teenagers. The number of starters is decreasing, indicating a more restrictive attitude toward first 
use, especially among general practitioners.  
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ATC code Anatomical Therapeutic Chemical classification system code 
BMD  bone mineral density 
DMPA depot medroxyprogesterone acetate 
BMI  body mass index 
LNG-IUD levonorgestrel releasing-intrauterine device  





Overall use of DMPA was relatively stable in Norway during the study period. Decreasing trends 
in starters of DMPA were observed. General practitioners reduced prescriptions of DMPA 







Scandinavian (1–4), European (5–8), and American (8–10) studies have shown low user rates for 
depot medroxyprogesterone acetate (DMPA). In general, and for DMPA in particular, there are 
few direct comparative studies with other contraceptives. 
 DMPA use has been a controversial issue in recent years, as the metabolites reduce serum 
estrogen levels, which in turn reduce bone mineral density (BMD) (11).  Young, long-term users 
in particular have shown a significant decline in BMD (12–16), which is reversible after 
discontinuation of DMPA (13, 15, 16). It is unclear whether changes in BMD during DMPA use 
influences later risk of fractures (17). In addition, research has demonstrated that DMPA has 
metabolic effects consistent with mild insulin resistance, weight gain, and increased fat mass, 
especially abdominally (18). A Brazilian study found greater increase in body mass index (BMI) 
over a three-year period in women, who at study start had BMI < 29.9 kg/m2 and used DMPA, 
than women who used a levonorgestrel intrauterine device (LNG-IUD) (19).  Similar results are 
reported from USA among young (12 to 18 years) obese (BMI > 30 kg / m2) women at baseline, 
who gained significantly more weight over an 18-month period than women who used oral 
hormonal contraception (9.5 kg compared to 0.2 kg) (20). However, the results on weight gain 
are controversial, as another USA study found no correlation between DMPA use and weight 
gain (21). 
 In Norway authorization of public health nurses and midwives as prescribers of oral 
contraceptives to women aged 16 to 19 years started in 2002 (22).  From March 1, 2006, this 
license expanded to cover DMPA, the vaginal ring and contraceptive patch, in addition to oral 
contraceptives (23).                             
 The debate on possible side effects of DMPA on BMD may influence prescription 
practice. The purpose of this study was to examine changes in DMPA prescriptions over a time-
period when new professions started as prescribers and the drug gained some negative media 
attention.  
 
Material and methods 
 
The Norwegian Prescription Database (NorPD) was established on January 1, 2004, and 
registered drugs delivered from pharmacies to users (24). A fictitious number is created from the 
personal identification number given to all Norwegians at birth or immigration.  These 
pseudonyms allow tracing of prescriptions for both users and prescribers over time. The NorPD 
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includes information on month and year of birth, gender, and users’ home municipality. Detailed 
information about the drugs are also registered. Subscriber information consists of gender, year 
of birth and graduation, profession, and year and type of specialty.  
From January 1, 2004 to June 30, 2013, 9 237 169 prescriptions of hormonal 
contraceptives (from Anatomical Therapeutic Chemical classification system codes (ATC codes) 
G02B and G03A) were registered in NorPD. We excluded contraceptive prescriptions to men 
(n=1 723), research-related contraceptive prescriptions (n=643), prescriptions to non-Norwegian 
citizens/persons with incomplete identity (n=11 890), and obvious errors in birth year (n=4 523). 
We also excluded prescriptions undertaken by dentists (n=1 065), dental assistants (n=369), 
veterinarians (n=74), opticians (N=19), and prescriptions with errors in number of packages 
delivered over the counter at pharmacies (n=959). In total, 9 215 904 valid prescriptions for 
hormonal contraceptives were identified, among which we identified 33 134 first-time DMPA 
users from January1, 2006 to December 31, 2012 as study participants. After excluding 115 
women who lacked information on year of birth and/or gender of prescriber, the study population 
comprised 33 019 first-time DMPA users. 
We estimated duration of use in months, from date of first collected DMPA prescription 
until the date of last continuous DMPA prescription, or date of prescription collection for other 
hormonal contraceptives. The study includes women who collected other hormonal contraceptive 
prescriptions at the same take out or within the first 20 days after a DMPA prescription, since this 
demonstrated an intention to start using DMPA. Use duration for this group was set to zero 
months.  
 “Switchers” began using DMPA within 28 days from expiration of last collected 
contraceptive, if last contraceptive was oral, vaginal ring, or a patch. We did not define a time 
limit in instances where last hormonal contraceptive was a LNG-IUD or an implant, since we do 
not know the exact time of removal before DMPA initiation. At study end, women who collected 
another hormonal contraceptive within 28 days after expiration of last DMPA prescription 
comprised the “switchers.” At study start, “pause” in use of hormonal contraception was 
restricted to women who submitted a DMPA prescription 29 days or later after expiration of the 
most recently collected contraceptive prescription. At study end, pause denoted women who 
collected another hormonal contraceptive 29 days or later after expiration of last dispensed 
DMPA prescription. Continuous DMPA users were women who collected another DMPA within 
29 days after expiration of the most recent delivery. 
 In the overall assessment of hormonal contraceptive consumption, we set the duration of 
implant use to 2 years (Implanon/Nexplanon) and 4 years (Jadelle), and the LNG-IUD 
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(LevoNova/Mirena) to 4 years.  For other hormonal contraceptives, we estimated annual number 
of users by calculating the daily doses sold per day/1000 women in 5-year age groups at 
reproductive age (15–49 years), depending on the number of packages and package size (as 
indicated in the ATC code) dispensed at each visit. Statistics Norway online service provided 
denominator data (age by calendar year) (25). 
 User age was categorized as 15–19, 20–24, 25–29, 30–34, 35–39, 40–44, and 45–49 
years, whereas prescriber age was categorized as 23–34, 35–44, 45–54, and 55–79 years. The 208 
starters aged 11 to 14 years were included in the 15–19 age group, while the 382 starters aged 50 
to 54 years were included in the 45–49 age group. Prescriber profession was categorized as 
general practitioner, gynecologist, other specialty, public health nurse, or midwife. Physicians 
without status as specialist in the NPD were categorized as doctors with no specialty. This 
category comprised postgraduate medical students who were doing their internship, physicians in 
a residency-training program, or medical students who had a contemporary license issued in the 
fifth year of medical school.  Physicians with more than one specialty were denoted with the 
most recent specialty.  
 Within the entire database, we created the variable “volume of prescriptions per 
provider,” categorized as < 10, 10 thru 23, 24 thru 47, and 48 or more prescriptions a year. 
 All analyses were done in Statistical Package for Social Sciences (SPSS) version 22.0, 
with chi-square tests for categorical variables, t-tests for continuous variables, and cumulative 
duration of use estimated by survival analysis with a significance level of p < 0.05.  
 
Ethical approval 
The NorPD board reviewed the protocol and gave permission for use of data (PDB 1459, saksnr. 
16/12041). Studies using anonymous data from nationwide registers are by Norwegian 





On a population level, the number of DMPA collections from pharmacies in Norway was 
relatively stable, across age and in total, during the study period (Table 1). The lowest and 
highest take-outs were consistent by year, lowest among women < 24 years and highest among 
40–44 years. The take-out number was equivalent to user rates of 11–12 per 1000 women of 
reproductive age 15–49 years (Table 1) and amounted to nearly 4% of all hormonal methods used 
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across the study years (Table 2). DMPA use relative to all other hormonal contraceptives 
increased significantly by age, with minor year-to-year differences (Table 2). 
 The number of DMPA starters decreased from nearly 6 200 in 2006 to 3 800 in 2012 
(Table 3).  There was a year-by-year reduction in first DMPA prescriptions among all age 
groups. Despite the declining number of starters, the relative age distribution remained consistent 
across study years, indicating an evenly distributed decrease in number of DMPA starters across 
age (Table 3).   
Most women who started using DMPA did so after a pause in hormonal contraception 
usage (Table 4, upper panel). The proportion of women without a previous registration in NorPD 
or a pause increased by age above 20 years.  More young women switched from oral 
contraceptives to DMPA, whereas older women may have switched from LNG-IUDs to DMPA.  
There were minor differences in the proportion of women switching from progestin-only pills to 
DMPA across age.  Only a small proportion of women switched from patch, vaginal ring, or 
implant to DMPA (Table 4, upper panel).  
 Within 29 days after the expiration of the last DMPA prescription, nearly 63% of starters 
did not collect any other hormonal contraceptive from pharmacies, indicating a pause in 
hormonal contraceptive use.  Sixteen percent continued with DMPA at study end, as indicated by 
prescriptions with duration beyond study end.  A significantly greater number of young users 
switched to oral contraceptives, while few DMPA users switched to vaginal ring, patch, 
progestin-only pills, implant, or LNG-IUD (Table 4, lower panel). 
 Except for women less than 20 years of age, male providers, versus female providers, 
prescribed more DMPA to starters (Table 5). Among providers below 45 years, females 
dominated in all professional groups listed in Table 5, whereas males dominated among providers 
45 years of age or above (data not shown). 
  Medical doctors without a specialty and general practitioners were the main DMPA 
providers. Gynecologists prescribed nearly 12% of all DMPA prescriptions to starters, relatively 
more DMPA to women 35 years or older than younger women.  Other specialist provided 4% of 
the total volume of prescriptions to starters, evenly distributed across age (Table 5).  Public 
health nurses/midwives prescribed nearly 20% of DMPA prescriptions to women 19 years or 
younger, which comprised 5% of the total volume of DMPA prescriptions across study years.    
 In Norway, contraceptive prescriptions are valid for four years. At each pharmacy visit, 
96% of the starters took out only one injection.  As one injection gives contraceptive protection 
for three months, the continuation rate will vary with the number of consecutive prescriptions 
refilled within the duration window. The average use duration among DMPA starters was 17.7 
8 
 
(95% CI: 17.5–17.9) months (range 0–90 months). We analyzed the cumulative proportion of 
starters that continued at 3, 6, 9, 12, 18, 24, 36, 48, and 60 months, including the 299 (0.9 %) 
women who collected another contraceptive prescription within 20 days of the DMPA 
prescription, under the assumption that these women did not start using DMPA but had an 
intention to start (intention-to-treat analysis). The cumulative proportion of users at 3 months was 
73% (95% CI: 72.6–73.6), at 6 months 59%, 9 months 50%, and 12 months 43%. The 
continuation rate declined further to 28%, 21%, 16%, and 13% at 24, 36, 48, and 60 months, 
respectively. After 12 months of use, the cumulative proportion of users was significantly higher 
for women 30 years or older compared to younger women. The estimates for cumulative 
proportions of starters that continued changed minimally after excluding the 299 women who 




DMPA plays a minor role in the overall use of hormonal contraception in Norway (Table 1 and 
2) and in the other Nordic countries (4). However, the overall DMPA use was lower in Denmark 
but higher in Sweden, especially among women above 35 years of age, compared to the 
Norwegian user pattern (4). According to WHO’s most updated data on contraceptive prevalence, 
the prevalence of DMPA use in 2013 was less than 2% in Austria, UK, and Finland, and 1% or 
lower in France, Germany, and Switzerland (8). Across continents, prevalence was highest in the 
Caribbean, Central- and South-America (5–7%), while being much lower in Europe (0.7%) and 
North-America (0.1%) (8).  Data from the 2011–2013 National Survey of Family Growth in the 
US did not report separate data on DMPA but summarized the use of vaginal ring, patch, and 
DMPA to 4.4% (10), similar to DMPA use data reported from the most recent contraceptive 
survey in France (8).  Among first contacts within the Sexual and Reproductive Health surveys in 
England over the years 2013–2014, a 9% prevalence was reported (6).  However, it is difficult to 
compare results across studies, since the definition of the denominators differed that much 
between studies.  
 We found a steady decline in starters in all age groups.  Among providers, general 
practitioners were the significant group in reducing DMPA prescriptions (data not shown).  
Prescriptions from gynecologists and MDs without a specialty declined slightly, whereas 
midwifes/public health nurses prescribed the same magnitude of DMPA across the study years. 
Judged by first prescriptions, we may speculate that public debates about the health risks of 
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DMPA could have prompted general practitioners to reduce DMPA prescriptions over the years, 
whereas the other professions showed little change in first prescriptions. 
 The continuation rate at 12 and 24 months (43% and 28%) of follow-up were lower than 
reported for DMPA users from the US-based CHOICE study (58% and 38%) (26). CHOICE, 
covering the 2007–2011 period, recruited women 14–45 years of age who had no desire to 
conceive within 12 months, and provided contraception at no cost for the participants (26). 
Similarly, case series assessing BMD by duration of use report higher continuation rates at two 
years than the present study (78% (12), 52% (13)). Women in clinical trials on contraceptive 
methods may be more motivated for long-term use than women provided the method on general 
terms. In addition, participation in clinical trial includes regular but shorter follow-up windows, 
better overall care, and investigators that may have an interest in keeping the women in the 
studies. All these factors, in addition to free contraception during trials, may explain lower 
continuation rates in the present register study relative to clinical trials like the CHOICE study 
(26).  
In Norway, all citizens have a right to choose a general practitioner from a list of 
authorized physicians (27). Over the study years, 99% of the target population of women at 
reproductive age had a regular doctor (27). Contraceptive counselling is considered a task for 
general practice, thus explaining why general practitioners were the main providers of DMPA at 
any age. Gynecologists contribute to contraceptive counselling, especially among older women 
of reproductive age, but far less than general practitioners and doctors with no specialty. The 
prescriber pattern for first prescriptions of DMPA in Norway is very similar to what has been 
reported for vaginal ring (28) and implants (29). 
To ease access to hormonal contraception in Norway, women 16–19 years of age receive 
a reimbursement of 100 NOK (~ 14 USD) for 3 months of use when the prescription is dispensed 
at the pharmacy (23).  In practice, DMPA has been free of charge for this subset of younger 
women over the study years. Despite this fact, DMPA use decreased among younger women over 
time (Table 1 and 2), as did the number of DMPA starters across all age groups (Table 3). 
Barriers toward DMPA use across the study years may be users’ and providers’ increased 
“beliefs” in weight gain, in addition to the possible providers’ concerns of DMPA’s effect on 
BMD in younger women. 
 
Conclusion  
The use of DMPA plays a minor role in the overall use of hormonal contraception in Norway. 
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The number of DMPA starters is declining. In particular, general practitioners are prescribing 
less DMPA to first-time users, whereas other professions show little or no change in prescription 
pattern over years with conflicting BMD data.    
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Table 1:  Estimated number of contraceptive DMPA users per 1000 women by age and 
calendar year. Norway 2006 through 2012 (‰) 
Year/ 
Age 
2006 2007 2008 2009 2010 2011 2012 
‰ ‰ ‰ ‰ ‰ ‰ ‰ 
15-19 8.7 8.7 8.7 8.3 8.0 7.9 7.6 
20-24 12.8 12.8 12.8 12.3 11.9 11.4 11.0 
25-29 11.2 11.2 11.2 11.0 10.8 10.6 10.4 
30-34 10.8 10.8 10.8 10.9 10.9 10.9 10.7 
35-39 13.8 13.8 13.8 13.8 13.9 14.1 14.3 
40-44 16.1 16.1 16.1 15.7 15.4 15.3 15.1 
45-49 11.8 11.8 11.8 11.7 11.5 11.3 11.0 
Total 12.3 12.3 12.3 12.1 11.9 11.7 11.6 
 
  
Table 2:  Estimated proportion of DMPA users out of all women using hormonal contraception 
by age and calendar year. Norway 2006 through 2012 (%). 
Year/ 
Age 
2006 2007 2008 2009 2010 2011 2012 
       
15-19 2.4 2.4 2.4 2.2 2.1 2.1 2.1 
20-24 2.4 2.5 2.4 2.3 2.2 2.1 2.0 
25-29 2.6 2.8 2.8 2.8 2.8 2.8 2.6 
30-34 3.2 3.3 3.3 3.4 3.5 3.5 3.3 
35-39 4.8 4.8 4.8 5.0 5.1 5.3 5.3 
40-44 7.6 7.4 7.3 7.0 6.9 6.9 6.5 
45-49 11.1 10.5 10.4 9.5 9.0 8.5 7.9 
Total 3.8 3.9 3.9 3.8 3.8 3.8 3.6 
        
 
  
Table 3:  DMPA starters by age and calendar year.  Norway 2006 through 2012 (%). 
Year/ 
Age 
2006 2007 2008 2009 2010 2011 2012 
N=6 186 N=5 660 N=5 914 N=4 227 N=4 212 N=4 021 N=3 799 
       
15-19 24.3 23.8 25.5 27.4 26.8 26.3 27.3 
20-24 19.7 19.0 18.3 17.9 19.5 21.2 20.6 
25-29 14.0 14.0 14.2 13.1 12.4 12.9 12.0 
30-34 13.5 14.9 13.1 12.4 12.0 12.0 11.5 
35-39 14.0 14.1 13.6 13.3 13.3 11.5 11.5 
40-44 9.3 9.1 9.7 10.5 10.0 10.0 9.4 
45-49 5.0 5.1 5.6 5.5 5.9 6.2 7.7 






Table 4:  Percentage of DMPA starters switching method at study start (upper panel) and at 
study end (lower panel) by age and total. Norway 2006 through 2012 (%). 
Age/ 
 
At study start  
15-19 20-24 25-29 30-34 35-39 40-44 45-49 Total 
N=8 485 N=6 411 N=4 407 N=4 273 N=4 357 N=3 192 N=1 894 N=33 019 
        
1st registr. in NPD  24.3 16.3 28.0 33.6 44.6 55.4 66.9 32.6 
Pause 32.3 47.0 42.9 37.6 29.0 21.5 14.1 34.8 
OCs 33.4 23.9 14.0 12.2 10.5 8.0 4.5 19.1 
Vaginal Ring 1.3 2.0 1.8 1.4 1.1 0.5 0.4 1.3 
Patch 2.1 2.2 1.9 1.4 1.1 0.7 0.2 1.6 
POPs 5.6 6.1 7.1 7.4 6.3 5.2 3.9 6.1 
Implant 0.7 1.1 1.0 1.0 1.1 0.7 0.6 0.9 
LNG-IUD 0.2 1.4 3.2 5.5 6.4 8.1 9.4 3.6 
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
At study end          
         
Pause 54.0 62.3 67.1 64.8 64.3 66.1 78.1 62.7 
OCs 21.2 14.4 11.1 8.1 5.3 3.7 1.6 11.9 
Vaginal Ring 2.0 1.7 1.2 1.3 0.6 0.5 0.2 1.3 
Patch 2.2 1.7 1.2 1.1 0.7 0.3 0.1 1.3 
POPs 4.0 4.3 4.1 3.7 3.1 2.1 2.0 3.6 
Continues with  DMPA 14.0 13.3 13.0 17.8 22.3 23.9 15.5 16.4 
Implant 2.3 1.4 0.7 0.9 0.8 0.4 0.1 1.2 
LNG-IUD 0.4 0.7 1.8 2.3 2.8 3.0 2.5 1.6 
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
1st registr. – 1st registration in the Norwegian Prescription Database. OCs = oral contraceptives. POPs= 








15-19 20-24 25-29 30-34 35-39 40-44 45-49 Total 
N=8 485 N=6 411 N=4 407 N=4 273 N=4 357 N=3 192 N=1 894 N=33 019 
        
Sex         
Male 40.7 53.0 56.1 58.0 57.8 55.7 52.5 51.8 
Female 59.3 47.0 43.9 42.0 42.2 44.3 47.5 48.2 
         
Medical specialty         
No specialty 33.7 38.4 37.4 33.8 29.9 26.6 23.3 33.4 
Gen. practitioners 38.9 47.6 49.1 50.0 51.9 46.8 37.2 45.8 
Other specialists 3.5 4.8 4.7 4.9 3.4 3.0 2.4 4.0 
Gynecologists 4.7 7.5 8.7 11.3 14.8 23.6 37.0 11.6 
Public health nurse 19.2 1.6      5.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
